benefit
(statisticaly significant)
benefit (nominaly significant, not statitically demonstrated) NS not significant harm statitically significant NS harm not significant low certainty due to bias
 
deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
abiraterone plus ADT vs. androgen deprivation therapy (ADT) 2 -37%
apalutamide plus ADT vs. androgen deprivation therapy (ADT) 1 -33%
docetaxel plus ADT vs. androgen deprivation therapy (ADT) 4 -24%
enzalutamide plus ADT vs. androgen deprivation therapy (ADT) 2 -34%
versus docetaxel plus ADT
abiraterone plus docetaxel plus ADT vs. docetaxel plus ADT 1 -25%
darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT 1 -32%